From Wikipedia, the free encyclopedia

Clinical data
Trade namesLaviv
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
ATC code
  • None
Legal status
Legal status

Azficel-T, sold under the brand name Laviv, is a cell therapy product for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.[1][2][3] It consists of fibroblasts harvested from the patient's own skin.[2]

It was approved for medical use in the United States in June 2011.[2]


  1. ^ a b "Laviv (Azficel-T)". U.S. Food and Drug Administration (FDA). 22 July 2017. Retrieved 1 April 2020.
  2. ^ a b c d "Autologous Fibroblasts". U.S. Food and Drug Administration (FDA). 29 June 2017. Archived from the original on 22 July 2017. Retrieved 1 April 2020.{{cite web}}: CS1 maint: unfit URL (link)
  3. ^ "Laviv (azficel-T) Suspension for Intradermal Injection" (PDF). Food and Drug Administration. Retrieved 2 April 2020.

Further reading[edit]

External links[edit]

  • "Azficel-T". Drug Information Portal. U.S. National Library of Medicine.
  • "Laviv (azficel-T)". Medscape. 28 September 2019.
  • Clinical trial number NCT02120781 for "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia" at